Brief: Mereo Biopharma Announces Pricing Of $50 Million Underwritten Registered Direct Offering
14/06/2024 12:52
June 14 (Reuters) - Mereo Biopharma Group PLC MAH0y.F :
* MEREO BIOPHARMA ANNOUNCES PRICING OF $50 MILLION
UNDERWRITTEN
REGISTERED DIRECT OFFERING OF AMERICAN DEPOSITORY SHARES, PRICED
AT-THE-MARKET
* PRICING OF UNDERWRITTEN OFFERING OF 12.5 MILLION ADSS
BEING SOLD
AT A PRICE OF $3.99 PER ADS
Source text for Eikon: ID:nGNX4yMMnF
Further company coverage: MAH0y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mereo BioPharma
See all newsBrief: Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Brief: Mereo BioPharma Q2 Operating Income USD -7.03 Million
Brief: Mereo BioPharma Q1 Net Income USD -6.719 Million
Brief: Mereo BioPharma FY Revenue USD 500 Thousand Vs. IBES Estimate USD 520 Thousand